Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 5 (2008), Issue 8 (August)

1. Effect of cyclosporine on reperfusion injury in acute myocardial infarction.
   N Engl J Med, 359(5): 473-81. [Abstract] [Full-text]
2. Perspectives on hormone replacement therapy: the Women's Health Initiative and new observational studies sampling the overall population.
   Fertil Steril, 90(2): 258-64. [Abstract] [Full-text]
3. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.
   J Clin Oncol, 26(22): 3756-62. [Abstract] [Full-text]
4. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.
   J Clin Oncol, 26(22): 3749-55. [Abstract] [Full-text]
5. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
   J Clin Oncol, 26(22): 3709-14. [Abstract] [Full-text]
6. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research.
   J Clin Oncol, 26(22): 3702-8. [Abstract] [Full-text]
7. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
   J Clin Oncol, 26(22): 3695-701. [Abstract] [Full-text]
8. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer.
   J Clin Oncol, 26(22): 3687-94. [Abstract] [Full-text]
9. Performance of self-diagnosis and standby treatment of malaria in international oilfield service employees in the field.
   Malar J, 7: 128. [Abstract] [Full-text]
10. Treatment of base of tongue cancer with paclitaxel, ifosfamide, and cisplatinum induction chemotherapy followed by chemoradiotherapy.
    Laryngoscope, 118(8): 1357-61. [Abstract] [Full-text]
11. The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential.
    Nat Rev Drug Discov, 7(8): 694-710. [Abstract] [Full-text]
12. Targeting bile-acid signalling for metabolic diseases.
    Nat Rev Drug Discov, 7(8): 678-93. [Abstract] [Full-text]
13. Design and evaluation of polypseudorotaxanes of pegylated insulin with cyclodextrins as sustained release system.
    Biomaterials, 29(28): 3866-71. [Abstract] [Full-text]
14. Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation.
    Biomaterials, 29(28): 3856-65. [Abstract] [Full-text]
15. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.
    JAMA, 300(5): 555-70. [Abstract] [Full-text]
16. Highly active antiretroviral therapy and survival in HIV-infected injection drug users.
    JAMA, 300(5): 550-4. [Abstract] [Full-text]
17. Conservative treatments of intraocular retinoblastoma.
    Ophthalmology, 115(8): 1405-10, 1410.e1-2. [Abstract] [Full-text]
18. Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen.
    Clin Cancer Res, 14(15): 4869-76. [Abstract] [Full-text]
19. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer.
    Clin Cancer Res, 14(15): 4843-9. [Abstract] [Full-text]
20. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.
    Clin Cancer Res, 14(15): 4836-42. [Abstract] [Full-text]
21. Progress and problems in the application of focused ultrasound for blood-brain barrier disruption.
    Ultrasonics, 48(4): 279-96. [Abstract] [Full-text]
22. Ultrasound enhanced thrombolysis in acute arterial ischemia.
    Ultrasonics, 48(4): 303-11. [Abstract] [Full-text]
23. Ultrasound thrombolysis.
    Ultrasonics, 48(4): 312-20. [Abstract] [Full-text]
24. Engineering of multifunctional gels integrating highly efficient growth factor delivery with endothelial cell transplantation.
    FASEB J, 22(8): 2949-56. [Abstract] [Full-text]
25. Sonodynamic therapy.
    Ultrasonics, 48(4): 253-9. [Abstract] [Full-text]
26. Drug-loaded nano/microbubbles for combining ultrasonography and targeted chemotherapy.
    Ultrasonics, 48(4): 260-70. [Abstract] [Full-text]
27. Application of percolation theory in the study of an extended release Verapamil hydrochloride formulation.
    Int J Pharm, 361(1): 112-7. [Abstract] [Full-text]
28. Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells.
    Int J Pharm, 361(1): 239-44. [Abstract] [Full-text]
29. Effect of poly(amidoamine) (PAMAM) dendrimer on skin permeation of 5-fluorouracil.
    Int J Pharm, 361(1): 230-8. [Abstract] [Full-text]
30. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes.
    Int J Pharm, 361(1): 104-11. [Abstract] [Full-text]
31. Ophthalmic delivery of Cyclosporine A from Brij-97 microemulsion and surfactant-laden p-HEMA hydrogels.
    Int J Pharm, 361(1): 222-9. [Abstract] [Full-text]
32. Preparation and in vitro evaluation of liposomal chloroquine diphosphate loaded by a transmembrane pH-gradient method.
    Int J Pharm, 361(1): 56-63. [Abstract] [Full-text]
33. Drug release behavior from in situ gelatinized thermosensitive nanogel aqueous dispersions.
    Int J Pharm, 361(1): 189-93. [Abstract] [Full-text]
34. Microwave generated solid dispersions containing Ibuprofen.
    Int J Pharm, 361(1): 125-30. [Abstract] [Full-text]
35. Isolated swine heart ventricle perfusion model for implant assisted-magnetic drug targeting.
    Int J Pharm, 361(1): 202-8. [Abstract] [Full-text]
36. Electrospun fibers of acid-labile biodegradable polymers with acetal groups as potential drug carriers.
    Int J Pharm, 361(1): 47-55. [Abstract] [Full-text]
37. Drug loading and release properties of ion-exchange resin complexes as a drug delivery matrix.
    Int J Pharm, 361(1): 26-32. [Abstract] [Full-text]
38. Folate-functionalized polymeric micelle as hepatic carcinoma-targeted, MRI-ultrasensitive delivery system of antitumor drugs.
    Biomed Microdevices, 10(5): 693-700. [Abstract] [Full-text]
39. Microneedle-based drug delivery: studies on delivery parameters and biocompatibility.
    Biomed Microdevices, 10(5): 601-10. [Abstract] [Full-text]
40. Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial.
    Br J Cancer, 99(3): 455-8. [Abstract] [Full-text]
41. DNA polymerases as therapeutic targets.
    Biochemistry, 47(32): 8253-60. [Abstract] [Full-text]
42. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
    J Natl Cancer Inst, 100(15): 1058-67. [Abstract] [Full-text]
43. Development, characterization, and evaluation of ketorolac tromethamine-loaded biodegradable microspheres as a depot system for parenteral delivery.
    Drug Deliv, 15(6): 365-72. [Abstract] [Full-text]
44. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial.
    Cancer, 113(4): 723-32. [Abstract] [Full-text]
45. Combination of dexamethasone, high-dose cytarabine, and carboplatin is effective for advanced large-cell non-Hodgkin lymphoma of childhood.
    Cancer, 113(4): 782-90. [Abstract] [Full-text]
46. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
    Cancer, 113(4): 808-14. [Abstract] [Full-text]
47. Adjuvant treatments do not alter the quality of life in elderly patients with colorectal cancer: a population-based study.
    Cancer, 113(4): 879-86. [Abstract] [Full-text]
48. Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib.
    Blood, 112(4): 1346-56. [Abstract] [Full-text]
49. EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma.
    Blood, 112(4): 1039-41. [Abstract] [Full-text]
50. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
    Blood, 112(4): 975-80. [Abstract] [Full-text]
51. Agreement between self-reported data on medicine use and prescription records vary according to method of analysis and therapeutic group.
    J Clin Epidemiol, 61(9): 919-24. [Abstract] [Full-text]
52. Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation.
    Biomaterials, 29(29): 4022-8. [Abstract] [Full-text]
53. Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging.
    Biomaterials, 29(29): 4012-21. [Abstract] [Full-text]
54. Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus.
    Gastroenterology, 135(2): 370-9. [Abstract] [Full-text]
55. The Malone antegrade continence enema: single institutional review.
    J Urol, 180(3): 1106-10. [Abstract] [Full-text]
56. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
    J Urol, 180(3): 867-72; discussion 872. [Abstract] [Full-text]
57. Complete pathological response of hepatocellular carcinoma with systemic combination chemotherapy.
    Anticancer Drugs, 19(8): 837-40. [Abstract] [Full-text]
58. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report.
    Anticancer Drugs, 19(8): 832-6. [Abstract] [Full-text]
59. Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer.
    Anticancer Drugs, 19(8): 825-31. [Abstract] [Full-text]
60. Differential effects of photodynamic therapy on morphologically distinct tumor cells derived from a single precursor cell.
    Cancer Lett, 268(2): 244-51. [Abstract] [Full-text]
61. Controlled delivery of platelet-rich plasma-derived growth factors for bone formation.
    J Biomed Mater Res A, 86(4): 1128-36. [Abstract] [Full-text]
62. Physicochemical characterization, in vitro, and in vivo evaluation of indomethacin-loaded nanocarriers self-assembled by amphiphilic polyphosphazene.
    J Biomed Mater Res A, 86(4): 914-25. [Abstract] [Full-text]
63. Supramolecular hydrogels based on inclusion complexation between poly(ethylene oxide)-b-poly (epsilon-caprolactone) diblock copolymer and alpha-cyclodextrin and their controlled release property.
    J Biomed Mater Res A, 86(4): 1055-61. [Abstract] [Full-text]
64. Antibiotic prophylaxis in dermatologic surgery: advisory statement 2008.
    J Am Acad Dermatol, 59(3): 464-73. [Abstract] [Full-text]
65. Does hormone therapy improve age-related skin changes in postmenopausal women? A randomized, double-blind, double-dummy, placebo-controlled multicenter study assessing the effects of norethindrone acetate and ethinyl estradiol in the improvement of mild to moderate age-related skin changes in postmenopausal women.
    J Am Acad Dermatol, 59(3): 397-404.e3. [Abstract] [Full-text]
66. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
    BJU Int, 102(5): 551-5. [Abstract] [Full-text]
67. The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data.
    BJU Int, 102(5): 622-7. [Abstract] [Full-text]
68. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses.
    BJU Int, 102(5): 556-62. [Abstract] [Full-text]
69. The effects of depilatory agents as penetration enhancers on human stratum corneum structures.
    J Invest Dermatol, 128(9): 2240-7. [Abstract] [Full-text]
70. tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation.
    Br J Cancer, 99(4): 597-603. [Abstract] [Full-text]
71. Acidic microclimate pH distribution in PLGA microspheres monitored by confocal laser scanning microscopy.
    Pharm Res, 25(9): 2041-52. [Abstract] [Full-text]
72. Photocytotoxicity of mTHPC (temoporfin) loaded polymeric micelles mediated by lipase catalyzed degradation.
    Pharm Res, 25(9): 2065-73. [Abstract] [Full-text]
73. Contrast-enhanced MRI-guided photodynamic cancer therapy with a pegylated bifunctional polymer conjugate.
    Pharm Res, 25(9): 2002-11. [Abstract] [Full-text]
74. A novel nanocapsule delivery system to overcome intestinal degradation and drug transport limited absorption of P-glycoprotein substrate drugs.
    Pharm Res, 25(9): 2019-29. [Abstract] [Full-text]
75. Doxorubicin loaded pH-sensitive micelle: antitumoral efficacy against ovarian A2780/DOXR tumor.
    Pharm Res, 25(9): 2074-82. [Abstract] [Full-text]
76. Combination antifungal therapy involving amphotericin B, rapamycin and 5-fluorocytosine using PEG-phospholipid micelles.
    Pharm Res, 25(9): 2056-64. [Abstract] [Full-text]
77. Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer.
    Br J Cancer, 99(4): 577-83. [Abstract] [Full-text]
78. A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei.
    Br J Cancer, 99(4): 591-6. [Abstract] [Full-text]
79. Chemoprevention of dibenzo[a,l]pyrene transplacental carcinogenesis in mice born to mothers administered green tea: primary role of caffeine.
    Carcinogenesis, 29(8): 1581-6. [Abstract] [Full-text]
80. Retroperitoneal lymph node dissection after chemotherapy for germ cell tumours: is a full bilateral template always necessary?
    BJU Int, 102(3): 310-4. [Abstract] [Full-text]
81. Preparation of Carbopol/chitosan interpolymer complex as a controlled release tablet matrix; effect of complex formation medium on drug release characteristics.
    Arch Pharm Res, 31(7): 932-7. [Abstract] [Full-text]
82. Efficacy of site-independent telemedicine in the STRokE DOC trial: a randomised, blinded, prospective study.
    Lancet Neurol, 7(9): 787-95. [Abstract] [Full-text]
83. Failure to restore the Vgamma2-Jgamma1.2 repertoire in HIV-infected men receiving highly active antiretroviral therapy (HAART).
    Clin Immunol, 128(3): 349-57. [Abstract] [Full-text]
84. A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients.
    Virology, 379(1): 78-86. [Abstract] [Full-text]
85. A novel density-tunable nanocomposites of CdTe quantum dots linked to dendrimer-tethered multi-wall carbon nanotubes.
    Spectrochim Acta A Mol Biomol Spectrosc, 70(5): 966-72. [Abstract] [Full-text]
86. Generation of multilayered structures for biomedical applications using a novel tri-needle coaxial device and electrohydrodynamic flow.
    J R Soc Interface, 5(27): 1255-61. [Abstract] [Full-text]
87. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer.
    J Clin Oncol, 26(24): 3979-86. [Abstract] [Full-text]
88. Reinduction platform for children with first marrow relapse in acute lymphoblastic lymphoma.
    J Clin Oncol, 26(24): 3971-8. [Abstract] [Full-text]
89. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment.
    J Clin Oncol, 26(24): 3950-7. [Abstract] [Full-text]
90. Human breast cancer tumor models: molecular imaging of drug susceptibility and dosing during HER2/neu-targeted therapy.
    Radiology, 248(3): 925-35. [Abstract] [Full-text]
91. Premedication to reduce discomfort during screening mammography.
    Radiology, 248(3): 765-72. [Abstract] [Full-text]
92. Treatment with melagatran alone or in combination with thrombolytic therapy reduced ischemic brain injury.
    Exp Neurol, 213(1): 171-5. [Abstract] [Full-text]
93. Efficacy of polidocanol foam versus liquid in sclerotherapy of the great saphenous vein: a multicentre randomised controlled trial with a 2-year follow-up.
    Eur J Vasc Endovasc Surg, 36(3): 366-70. [Abstract] [Full-text]
94. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
    J Natl Cancer Inst, 100(16): 1167-78. [Abstract] [Full-text]
95. Application of software design principles and debugging methods to an analgesia prescription reduces risk of severe injury from medical use of opioids.
    Clin Pharmacol Ther, 84(3): 385-92. [Abstract] [Full-text]
96. Scoring system for predicting response to chemoradiotherapy, including 5-Fluorouracil and platinum, for patients with esophageal cancer.
    Dig Dis Sci, 53(9): 2415-21. [Abstract] [Full-text]
97. Photodynamic therapy with methyl aminolevulinate for prevention of new skin lesions in transplant recipients: a randomized study.
    Transplantation, 86(3): 423-9. [Abstract] [Full-text]
98. Lipoprotein particle concentrations may explain the absence of coronary protection in the women's health initiative hormone trials.
    Arterioscler Thromb Vasc Biol, 28(9): 1666-71. [Abstract] [Full-text]
99. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study.
    Diabetes Technol Ther, 10(5): 377-83. [Abstract] [Full-text]
100. SBA-15 ordered mesoporous silica inside a bioactive glass-ceramic scaffold for local drug delivery.
     J Mater Sci Mater Med, 19(10): 3303-10. [Abstract] [Full-text]
101. Intracarotid delivery of drugs: the potential and the pitfalls.
     Anesthesiology, 109(3): 543-64. [Abstract] [Full-text]
102. Toll-like receptor-4 is expressed in meningiomas and mediates the antiproliferative action of paclitaxel.
     Int J Cancer, 123(8): 1956-63. [Abstract] [Full-text]
103. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
     Cancer Lett, 269(1): 7-17. [Abstract] [Full-text]
104. Care of the HIV-positive patient in the emergency department in the era of highly active antiretroviral therapy.
     Ann Emerg Med, 52(3): 274-85. [Abstract] [Full-text]
105. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
     Am J Cardiol, 102(5): 552-8. [Abstract] [Full-text]
106. Impact of optimal medical therapy and revascularization on outcome of patients with chronic kidney disease and on dialysis who presented with acute coronary syndrome.
     Am J Cardiol, 102(5): 535-40. [Abstract] [Full-text]
107. In vitro amoebacidal activity of photodynamic therapy on Acanthamoeba.
     Br J Ophthalmol, 92(9): 1283-6. [Abstract] [Full-text]
108. Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to alpha-particle emitting 211 At.
     Int J Radiat Oncol Biol Phys, 72(1): 193-200. [Abstract] [Full-text]
109. Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297.
     Int J Radiat Oncol Biol Phys, 72(1): 108-13. [Abstract] [Full-text]
110. Third- and fourth-generation fluoroquinolones: retrospective comparison of endophthalmitis after cataract surgery performed over 10 years.
     J Cataract Refract Surg, 34(9): 1460-7. [Abstract] [Full-text]
111. Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery.
     J Cataract Refract Surg, 34(9): 1451-9. [Abstract] [Full-text]
112. Clinical manifestations and treatment of retinoblastoma in Korea.
     Br J Ophthalmol, 92(9): 1180-4. [Abstract] [Full-text]
113. Pharmacogenetics of hormone replacement therapy for climacteric symptoms.
     Biochem Biophys Res Commun, 374(4): 604-8. [Abstract] [Full-text]
114. EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.
     Int J Radiat Oncol Biol Phys, 72(1): 119-26. [Abstract] [Full-text]
115. Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08.
     Int J Radiat Oncol Biol Phys, 72(1): 114-8. [Abstract] [Full-text]
116. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis.
     CMAJ, 179(5): 438-46. [Abstract] [Full-text]
117. The eldest of older adults living with HIV: response and adherence to highly active antiretroviral therapy.
     Am J Med, 121(9): 820-4. [Abstract] [Full-text]
118. Increasing age at HIV seroconversion from 18 to 40 years is associated with favorable virologic and immunologic responses to HAART.
     J Acquir Immune Defic Syndr, 49(1): 40-7. [Abstract] [Full-text]
119. Evaluation of a systematic substitution of zidovudine for stavudine-based HAART in a program setting in rural Cambodia.
     J Acquir Immune Defic Syndr, 49(1): 48-54. [Abstract] [Full-text]
120. Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study.
     J Acquir Immune Defic Syndr, 49(1): 26-31. [Abstract] [Full-text]
121. Antiretroviral failure despite high levels of adherence: discordant adherence-response relationship in Botswana.
     J Acquir Immune Defic Syndr, 49(1): 107-10. [Abstract] [Full-text]
122. HIV drug resistance pattern among HAART-exposed patients with suboptimal virological response in Ouagadougou, Burkina Faso.
     J Acquir Immune Defic Syndr, 49(1): 17-25. [Abstract] [Full-text]
123. CD4 cell response before and after HAART initiation according to viral load and growth indicators in HIV-1-infected children in Abidjan, Côte d'Ivoire.
     J Acquir Immune Defic Syndr, 49(1): 70-6. [Abstract] [Full-text]
124. The MRA-DWI mismatch identifies patients with stroke who are likely to benefit from reperfusion.
     Stroke, 39(9): 2491-6. [Abstract] [Full-text]
125. In-hospital stroke treated with intravenous tissue plasminogen activator.
     Stroke, 39(9): 2614-6. [Abstract] [Full-text]
126. Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen.
     Cancer, 113(5): 945-55. [Abstract] [Full-text]
127. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies.
     Blood, 112(5): 1646-54. [Abstract] [Full-text]
128. Surfactant dependent morphology of polymeric capsules of perfluorooctyl bromide: influence of polymer adsorption at the dichloromethane-water interface.
     J Colloid Interface Sci, 326(1): 66-71. [Abstract] [Full-text]
129. Layer-by-layer assembled thin films composed of carboxyl-terminated poly(amidoamine) dendrimer as a pH-sensitive nano-device.
     J Colloid Interface Sci, 326(1): 35-40. [Abstract] [Full-text]
130. Preparation and characterization of cross-linked enzyme aggregates (CLEA) of subtilisin for controlled release applications.
     Int J Biol Macromol, 43(3): 314-9. [Abstract] [Full-text]
131. The use of solid lipid nanoparticles to target a lipophilic molecule to the liver after intravenous administration to mice.
     Int J Biol Macromol, 43(3): 320-4. [Abstract] [Full-text]
132. A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer.
     Br J Cancer, 99(5): 722-6. [Abstract] [Full-text]
133. Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer.
     Br J Cancer, 99(5): 711-5. [Abstract] [Full-text]
134. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.
     Br J Cancer, 99(5): 800-4. [Abstract] [Full-text]
135. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
     N Engl J Med, 359(9): 906-17. [Abstract] [Full-text]
136. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
     Oncogene, 27(37): 5019-32. [Abstract] [Full-text]
137. Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy.
     J Surg Oncol, 98(4): 247-52. [Abstract] [Full-text]
138. Age-dependent impairment of HIF-1alpha expression in diabetic mice: Correction with electroporation-facilitated gene therapy increases wound healing, angiogenesis, and circulating angiogenic cells.
     J Cell Physiol, 217(2): 319-27. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.